Endos506 1__7

The incidence of esophageal tumors, and of adenocarcinoma in particular, has risen markedly in recent years in the developed countries. The use of a variety of histopathological and biological markers is now offering promising prospects for the future. Vertical tumor invasion, intratumoral microvessel density, antimucin monoclonal antibodies, flow cytometry, telomerase activity, and overexpression of cyclin D1 have been correlated with the staging and prognosis of esophageal carcinomas. By combining these markers with Lugol staining, a practical new method of staging esophageal tumors may become available in the coming years.

[1]  C. Gostout,et al.  Histopathologic findings predicting lymph node metastasis and prognosis of patients with superficial esophageal carcinoma. Analysis of 240 surgically resected tumors. , 2001, Gastrointestinal endoscopy.

[2]  H. Goto,et al.  Evaluation of prognosis of squamous cell carcinoma of the oesophagus by endoscopic ultrasonography , 2000, Gut.

[3]  M. Seto,et al.  Cyclin D1 Expression Is Useful as a Prognostic Indicator for Advanced Esophageal Carcinomas, but Not for Superficial Tumors , 2000, Digestive Diseases and Sciences.

[4]  A. Stewart,et al.  Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. , 2000, Journal of the American College of Surgeons.

[5]  M. Stolte,et al.  Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. , 2000, Gastroenterology.

[6]  Y. Doki,et al.  Clinical application of malignancy potential grading as a prognostic factor of human esophageal cancers. , 2000, Surgery.

[7]  Shiro Kikuchi,et al.  Measuring the Tumor Volume of Gastric Carcinoma by Computer Image Analysis: Clinical Significance , 2000, World Journal of Surgery.

[8]  B. Reid,et al.  Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus , 2000, Annals of Internal Medicine.

[9]  H. Tajiri,et al.  Correlation of in vitro autofluorescence endoscopy images with histopathologic findings in stomach cancer. , 2000, Endoscopy.

[10]  M. Bramble,et al.  Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy , 2000, Gut.

[11]  M. Kitajima,et al.  Telomerase activity as an indicator of malignant potential in iodine‐nonreactive lesions of the esophagus , 2000, Cancer.

[12]  T. Saclarides,et al.  Do Angiogenesis and Growth Factor Expression Predict Prognosis of Esophageal Cancer? , 2000, The American surgeon.

[13]  J. Wayman,et al.  Prescription of proton pump inhibitors before endoscopy. A potential cause of missed diagnosis of early gastric cancers. , 2000, Archives of family medicine.

[14]  I. Salmon,et al.  Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus , 2000, Gut.

[15]  M. Kitajima,et al.  Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  G. Tytgat,et al.  Intestinal and pancreatic metaplasia at the esophagogastric junction in patients without Barrett's esophagus. , 2000 .

[17]  M. Mayo,et al.  Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia , 2000, Gut.

[18]  M. Verhoef,et al.  Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia , 2000, Gut.

[19]  M. Younes, J. Lechago, S. Chakraborty, M. Ostrowsk,et al.  Relationship between Dysplasia, p53 Protein Accumulation, DNA Ploidy, and Glut1 Overexpression in Barrett Metaplasia , 2000 .

[20]  F. Borchard,et al.  Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of barrett esophagus , 1999, Cancer.

[21]  A. Weston,et al.  Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma , 1999, American Journal of Gastroenterology.

[22]  Mason,et al.  Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation , 1999, Histopathology.

[23]  A. Munakata,et al.  Most gastric cancer occurs on the distal side of the endoscopic atrophic border. , 1999, Scandinavian journal of gastroenterology.

[24]  R. Horvat,et al.  Prospective long-term endoscopic and histologic follow-up of gastric lymphoproliferative disease of early stage IE low-grade B-cell mucosa-associated lymphoid tissue type following Helicobacter pylori eradication treatment. , 1999, International journal of oncology.

[25]  R. Fujita,et al.  Diagnosis of submucosal tumor of the upper GI tract by endoscopic resection. , 1999, Gastrointestinal endoscopy.

[26]  H. Goto,et al.  The utility of endoscopic ultrasonography and endoscopy in the endoscopic mucosal resection of early gastric cancer , 1999, Gut.

[27]  G. Gasbarrini,et al.  Minimal endoscopic aspects of gastric low-grade malt-lymphoma. , 1999, Hepato-gastroenterology.

[28]  H. Hibshoosh,et al.  Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. , 1999, Human pathology.

[29]  O. Garden,et al.  Role of laparoscopic ultrasonography in the management of patients with oesophagogastric cancer , 1999, The British journal of surgery.

[30]  G. Falk,et al.  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999, American Journal of Gastroenterology.

[31]  N. Kinukawa,et al.  Gastric carcinoma confined to the Muscularis propria: how can we detect, evaluate, and cure intermediate-stage carcinoma of the stomach? , 1999, American Journal of Gastroenterology.

[32]  E. G. Hahn,et al.  Endoscopic photodynamic diagnosis: oral aminolevulinic acid is a marker of GI cancer and dysplastic lesions. , 1999, Gastrointestinal endoscopy.

[33]  Jeffrey E. Lee,et al.  Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial , 1999, Annals of Internal Medicine.

[34]  D. Chang,et al.  Lymph node involvement rate in low-grade gastric mucosa-associated lymphoid tissue lymphoma--too high to be neglected. , 1999, Hepato-gastroenterology.

[35]  J. Dam,et al.  Increased rate of complete EUS staging of patients with esophageal cancer using the nonoptical, wire-guided echoendoscope. , 1999, Gastrointestinal endoscopy.

[36]  R. Odze,et al.  Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. , 1999, Human pathology.

[37]  P. Duray,et al.  Polypoid dysplasia in Barrett's esophagus: a clinicopathologic, immunohistochemical, and molecular study of five cases. , 1999, Human pathology.

[38]  A. Vecchione,et al.  Gastric pathology in patients with common variable immunodeficiency , 1999, Gut.

[39]  O. Nyrén,et al.  No association between colon cancer and adenocarcinoma of the oesophagus in a population based cohort study in Sweden , 1999, Gut.

[40]  N. Sadanaga,et al.  Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus , 1999, Cancer.

[41]  H. Feußner,et al.  Pretherapeutic laparoscopic staging in advanced gastric carcinoma. , 1999, Endoscopy.

[42]  J. Lagergren,et al.  Association between Body Mass and Adenocarcinoma of the Esophagus and Gastric Cardia , 1999, Annals of Internal Medicine.

[43]  E. Mello,et al.  Occult dysplasia is disclosed by Lugol chromoendoscopy in alcoholics at high risk for squamous cell carcinoma of the esophagus. , 1999, Endoscopy.

[44]  W. Domschke,et al.  Preoperative staging of esophageal carcinoma: miniprobe sonography versus conventional endoscopic ultrasound in a prospective histopathologically verified study. , 1999, Endoscopy.

[45]  I. Cecconello,et al.  Lugol dye endoscopy for analysis of esophageal mucosa in achalasia. , 1999, Hepato-gastroenterology.

[46]  M A Fujino,et al.  Accuracy of screening for gastric cancer using serum pepsinogen concentrations , 1999, Gut.

[47]  相良 光久.  Expression of mucin 1(MUC1)in esophageal squamous-cell carcinoma : Its relationship with prognosis , 2001 .

[48]  A. Giménez,et al.  DNA Ploidy Status and Proliferative Activity as Markers of Malignant Potential in Barrett's Esophagus: Flow Cytometric Study Using Routinely Paraffin-embedded Tissue , 2000, World Journal of Surgery.

[49]  R. Willén,et al.  Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. , 2000, Scandinavian journal of gastroenterology.

[50]  S. Finkelstein,et al.  Integrated p53 histopathologic/genetic analysis of premalignant lesions of the esophagus. , 2000, Cancer detection and prevention.

[51]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[52]  H. Yokozaki,et al.  Microsatellite instability in squamous cell carcinomas and dysplasias of the esophagus. , 2000, Anticancer research.

[53]  Dawn Provenzale,et al.  Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk , 1999, American Journal of Gastroenterology.

[54]  Prateek Sharma,et al.  Biomarker studies in reversed Barrett's esophagus , 1999, American Journal of Gastroenterology.

[55]  H. Ono,et al.  Endoscopic and histological reversibility of gastric adenoma after eradication of Helicobacter pylori. , 1999, Journal of gastroenterology.